NCT06464965View on ClinicalTrials.gov

Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 19, 2024

Primary Completion Date

June 13, 2025

Study Completion Date

June 30, 2027

Conditions
Gastric CancerPancreas Adenocarcinoma
Interventions
BIOLOGICAL

CB CAR-NK182

To study the maximum tolerated dose (MTD) and dose-dependent toxicity (DLT) of cord blood-derived CAR-NK cells (CB CAR-NK182) targeting Claudin18.2 in patients with advanced gastric cancer and advanced pancreatic cancer

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Provincial People's Hospital, Hangzhou

All Listed Sponsors
collaborator

Zhejiang University

OTHER

collaborator

Hangzhou RongGu Biotechnology Limited Company

UNKNOWN

lead

Zhejiang Provincial People's Hospital

OTHER